Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Type:
Application
Filed:
June 14, 2022
Publication date:
December 8, 2022
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
Abstract: The present disclosure provides methods of imaging cancerous cells in a subject, wherein the cancerous cells are localized to the skeletal system or central nervous system of the subject, the method comprising administering to the subject an effective amount of 18F-fluoroacetate, detecting a first signal emitted by 18F-fluoroacetate, and generating an image representative of the location and/or amount of the first signal to image the cancerous cells. In some embodiments, the methods further comprising diagnosing, prognosing, staging, and/or monitoring the progression of a disease or disorder, such as acute lymphoblastic leukemia and/or leptomeningeal disease.
Type:
Application
Filed:
November 4, 2020
Publication date:
December 8, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: Provided herein are methods of treating a dysmyelinating/demyelinating disease or condition in a patient in need thereof. The methods comprise restoring Qki-PPAR?-RXR?-dependent lipid metabolism in myelin. For example, the methods comprise administering a PPAR? agonist or an RXR agonist to the patient.
Type:
Application
Filed:
November 6, 2020
Publication date:
December 8, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.
Type:
Application
Filed:
October 16, 2020
Publication date:
December 8, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: Disclosed are air-stable small-molecule adsorbents trimeric [Cu—Br]3 and [Cu—H]3 that undergo a reversible solid-state molecular rearrangements to [Cu—Br.(alkene)]2 and [Cu—H.(alkene)]2 dimers. The reversible solid-state rearrangement allows one to break adsorbent design trade-offs and achieve low heat of adsorption while retaining high selectivity and uptake.
Type:
Grant
Filed:
June 23, 2021
Date of Patent:
December 6, 2022
Assignees:
Board of Regents, The University of Texas System, University of Canterbury
Inventors:
Rasika Dias, Matthew Greig Cowan, Devaborniny Parasar
Abstract: A method, system and computer program product for reducing the amount of helper data that needs to be stored using two innovative techniques. The first technique uses bit-error-rate (BER)-aware lossy compression. By treating a fraction of reliable bits as unreliable, it effectively reduces the size of the reliability mask. With the view of practical costs of production-time error characterization, the second technique enables economically feasible across-temperature per-bit BER evaluation for use in a number of fuzzy extractor optimizations based on bit-selection to reduce overall BER (with or without subsequent compression) using room-temperature only production-time characterization. The technique is based on stochastic concentration theory and allows efficiently forming confidence intervals for average across-temperature BER of a selected set of bits.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
December 6, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: Disclosed herein are nanostructured plasmonic materials. The nanostructured plasmonic materials can include a first nanostructured layer comprising: a first layer of a first plasmonic material permeated by a first plurality of spaced-apart holes, wherein the first plurality of spaced apart holes comprise a first array; and a second nanostructured layer comprising a second layer of a second plasmonic material permeated by a second plurality of spaced-apart holes, wherein the second plurality of spaced apart holes comprise a second array; wherein the second nanostructured layer is located proximate the first nanostructured layer; and wherein the first principle axis of the first array is rotated at a rotation angle compared to the first principle axis of the second array.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
December 6, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
December 6, 2022
Assignee:
The Board of Regents of The University of Texas System
Abstract: Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.
Type:
Grant
Filed:
December 20, 2021
Date of Patent:
December 6, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
William S Charlton, Donald D. Nolting, Adam J. Samia, Joseph Lapka
Abstract: The present disclosure relates to degradable polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and have backbones which are capable of undergoing degradation in vivo. In some aspects, the disclosure also provides methods of using these degradable polymers for the delivery of a drug.
Type:
Application
Filed:
June 22, 2020
Publication date:
December 1, 2022
Applicant:
The Board of Regents of The University of Texas System
Inventors:
Jinming GAO, Xu WANG, Houliang TANG, Wei LI, Jonathan WILHELM, Baran SUMER
Abstract: Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
Type:
Application
Filed:
December 16, 2019
Publication date:
December 1, 2022
Applicants:
Board of Regents, The University of Texas System, Consiglio Nazionale delle Ricerche
Inventors:
Gabriel LOPEZ-BERESTEIN, Paola AMERO, Cristian RODRIGUEZ-AGUAYO, Rahul MITRA, Anil K. SOOD, Vittorio DE FRANCISCIS, David VOLK, Lokesh Ganesh L. RAO
Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Type:
Application
Filed:
July 22, 2022
Publication date:
December 1, 2022
Applicants:
Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
Inventors:
Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
Type:
Application
Filed:
July 21, 2022
Publication date:
December 1, 2022
Applicant:
Board of Regents, The University of Texas System
Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a p53 mutation by administering an inhibitor of nonsense mediated decay. The patient may be further administered an inhibitor of mRNA splicing and/or an inhibitor of MDM.
Type:
Application
Filed:
November 2, 2020
Publication date:
December 1, 2022
Applicant:
Board of Regents, The University of Texas System
Inventors:
John V. HEYMACH, Jayanthi GUDIKOTE, Tina CASCONE
Abstract: The techniques described herein may provide an efficient and secure two-party distributed signing protocol for the identity-based signature scheme described in the IEEE P1363 standard. For example, in an embodiment, a method may comprise generating a distributed cryptographic key at a key generation center and a first other device and a second other device and generating a distributed cryptographic signature at the first other device using the second other device.
Type:
Grant
Filed:
July 2, 2019
Date of Patent:
November 29, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: A device for measuring strain on the exterior of a pipe includes a body comprising a top portion and a bottom portion; one or more elastically deformable members coupled between the top portion and the bottom portion, wherein each of the one or more elastically deformable members have an outer contact surface and an inner non-contact surface. One or more sensors are disposed on the inner non-contact surface of one or more of the elastically deformable members. The sensors, during use, provide data that can be used to determine changes in strain on the exterior of the pipe. In another embodiment, one or more sensors are embedded in, or attached to, a casing disposed in a wellbore. In an embodiment, a method includes pressurizing or depressurizing the wellbore with a fluid and measuring the strain induced in the casing (or in an open wellbore) in response to this change in wellbore pressure.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
November 29, 2022
Assignee:
The Board of Regents of The University of Texas System
Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Type:
Grant
Filed:
April 1, 2022
Date of Patent:
November 29, 2022
Assignee:
The Board of Regents of The University of Texas System
Inventors:
Qiang Cheng, Tuo Wei, Daniel J. Siegwart
Abstract: Provided herein are anti-FGL2 monoclonal antibodies. Further provided herein are methods to reverse suppressive immune mechanisms, such as for the treatment of cancer or infectious diseases.
Type:
Grant
Filed:
May 7, 2018
Date of Patent:
November 29, 2022
Assignee:
Board of Regents, The University of Texas System
Abstract: The present disclosure provides a domain wall magnetic tunnel junction device. Integration of input spikes pushes a domain wall within a ferromagnetic track toward a magnetic tunnel junction (MTJ). An energy gradient within the track pushes the domain wall away from the MTJ by leaking accumulated energy from the input spikes. If the integrated input spikes exceed the energy leak of the gradient within a specified time period, the domain wall reaches the MTJ and reverses its resistance, producing an output spike. The leaking energy gradient can be created by a magnetic field, a trapezoidal shape of the ferromagnetic track, or nonuniform material properties in the ferromagnetic track.
Type:
Grant
Filed:
January 29, 2020
Date of Patent:
November 29, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Joseph S. Friedman, Wesley H. Brigner, Naimul Hassan, Xuan Hu
Abstract: Provided are methods for the production of infinite immune cells with an increased lifespan and high proliferation rates by engineering them to express BCL6 and a cell survival-promoting gene. Further provided herein are methods for the production and use of the infinite immune cells for the treatment of diseases, such as cancer.
Type:
Application
Filed:
August 19, 2020
Publication date:
November 24, 2022
Applicant:
Board of Regents, The University of Texas System